Kazia Therapeutics Limited Revenue | KZIA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Kazia Therapeutics Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
42 K	2.31 M	-	-	-	-	-	119 K	249 K	406 K	-	-	1.07 M	1.51 M	2.02 M

All numbers in AUD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.31 M	42 K	966 K

Quarterly Revenue Kazia Therapeutics Limited

2026-Q2	2025-Q4	2025-Q2	2024-Q2	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	2.31 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in AUD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.31 M	2.31 M	2.31 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Ionis Pharmaceuticals IONS	203 M	$ 43.5	0.62 %	$ 6.96 B	USA
Agios Pharmaceuticals AGIO	54 M	$ 31.25	0.88 %	$ 1.81 B	USA
Foghorn Therapeutics FHTX	30.9 M	$ 2.0	0.74 %	$ 126 M	USA
Inhibikase Therapeutics IKT	261 K	$ 2.0	0.5 %	$ 197 M	USA
Kamada Ltd. KMDA	180 M	$ 8.0	1.34 %	$ 461 M	Israel
Intellia Therapeutics NTLA	67.7 M	$ 12.75	4.0 %	$ 1.38 B	USA
Ultragenyx Pharmaceutical RARE	673 M	$ 14.5	3.19 %	$ 1.43 B	USA
Viridian Therapeutics VRDN	70.8 M	$ 19.0	2.16 %	$ 1.93 B	USA
AbbVie ABBV	16.6 B	$ 265.76	1.12 %	$ 470 B	USA
AbCellera Biologics ABCL	75.1 M	$ 13.78	0.29 %	$ 4.12 B	Canada
Abeona Therapeutics ABEO	5.82 M	$ 5.11	1.59 %	$ 271 M	USA
Arbutus Biopharma Corporation ABUS	14.1 M	$ 4.67	4.94 %	$ 895 M	Canada
ACADIA Pharmaceuticals ACAD	1.07 B	$ 20.11	0.8 %	$ 3.39 B	USA
Achieve Life Sciences ACHV	5.06 M	$ 7.01	0.13 %	$ 306 M	USA
AC Immune SA ACIU	3.57 M	$ 2.71	0.55 %	$ 273 M	Schweiz
Aclaris Therapeutics ACRS	7.83 M	$ 4.27	0.79 %	$ 523 M	USA
Adagene ADAG	7.67 M	$ 2.8	0.28 %	$ 165 M	China
ADC Therapeutics SA ADCT	81.4 M	$ 1.23	8.85 %	$ 156 M	Schweiz
ADMA Biologics ADMA	510 M	$ 10.11	4.01 %	$ 2.41 B	USA
Adaptive Biotechnologies Corporation ADPT	277 M	$ 29.84	5.26 %	$ 4.53 B	USA
Agenus AGEN	114 M	$ 8.73	4.43 %	$ 260 M	USA
AIM ImmunoTech AIM	88 K	$ 0.19	5.56 %	$ 308 K	USA
Akebia Therapeutics AKBA	236 M	$ 0.91	5.26 %	$ 234 M	USA
Akari Therapeutics, Plc AKTX	368 K	$ 8.76	0.46 %	$ 590 B	Britain
Alector ALEC	21 M	$ 1.99	9.94 %	$ 205 M	USA
Aligos Therapeutics ALGS	2.19 M	$ 5.4	0.36 %	$ 53.4 M	USA
Alkermes plc ALKS	1.48 B	$ 42.76	2.42 %	$ 7.04 B	Irlanda
Allogene Therapeutics ALLO	22 K	$ 1.5	0.33 %	$ 331 M	USA
Alnylam Pharmaceuticals ALNY	3.71 B	$ 219.89	0.08 %	$ 28.8 B	USA
Altimmune ALT	41 K	$ 2.67	0.36 %	$ 235 M	USA
ALX Oncology Holdings ALXO	1.18 M	$ 1.21	1.23 %	$ 64.9 M	USA
Amgen AMGN	36.8 B	$ 402.98	0.08 %	$ 217 B	USA
Amphastar Pharmaceuticals AMPH	720 M	$ 25.37	0.39 %	$ 1.19 B	USA
Amarin Corporation plc AMRN	214 M	$ 12.09	0.31 %	$ 5.02 B	Irlanda
Amneal Pharmaceuticals AMRX	3.02 B	$ 20.35	0.25 %	$ 6.38 B	USA
AnaptysBio ANAB	53 M	$ 49.2	1.38 %	$ 1.43 B	USA
Anika Therapeutics ANIK	113 M	$ 19.73	3.3 %	$ 283 M	USA
ANI Pharmaceuticals ANIP	883 M	$ 72.58	0.55 %	$ 1.46 B	USA
Aptevo Therapeutics APVO	3.11 M	$ 1.8	2.27 %	$ 568 K	USA
Aquestive Therapeutics AQST	44.5 M	$ 4.57	0.44 %	$ 489 M	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 14.66	12.51 %	$ 401 M	Israel
Ardelyx ARDX	407 M	$ 3.39	1.5 %	$ 817 M	USA
argenx SE ARGX	36.4 M	$ 912.87	1.28 %	$ 56 B	Niderland
Armata Pharmaceuticals ARMP	823 K	$ 3.66	3.98 %	$ 133 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 25.15	0.04 %	$ 3.2 B	USA